AGEN Stock Overview
A clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Agenus Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.83 |
| 52 Week High | US$19.69 |
| 52 Week Low | US$2.50 |
| Beta | 1.24 |
| 1 Month Change | -15.27% |
| 3 Month Change | -45.26% |
| 1 Year Change | -81.90% |
| 3 Year Change | -95.92% |
| 5 Year Change | -96.47% |
| Change since IPO | -99.96% |
Recent News & Updates
Recent updates
Agenus: Novel Drugs That Just Are Not Novel
Jul 24There's No Escaping Agenus Inc.'s (NASDAQ:AGEN) Muted Revenues Despite A 102% Share Price Rise
May 21
Analysts Have Lowered Expectations For Agenus Inc. (NASDAQ:AGEN) After Its Latest Results
May 09Benign Growth For Agenus Inc. (NASDAQ:AGEN) Underpins Stock's 25% Plummet
Mar 29Agenus: 2024 May Finally Be The Year For A Major Turnaround
Jan 18Improved Revenues Required Before Agenus Inc. (NASDAQ:AGEN) Shares Find Their Feet
Dec 22News Flash: Analysts Just Made A Huge Upgrade To Their Agenus Inc. (NASDAQ:AGEN) Forecasts
Nov 09A Look At The Fair Value Of Agenus Inc. (NASDAQ:AGEN)
Oct 04Industry Analysts Just Made A Notable Upgrade To Their Agenus Inc. (NASDAQ:AGEN) Revenue Forecasts
May 10VBI Vaccines, Agenus to examine VBI-1901 + balstilimab combo for glioblastoma
Oct 12Agenus New Trials Set It Up For The Long Haul
Sep 27Agenus: It's Always Tomorrow
Sep 16Agenus GAAP EPS of -$0.17, revenue of $20.93M
Aug 09Agenus: Successfully Pulled Itself Away From Disaster
Jul 04Agenus: Not Quite Enough
Apr 19Auditors Have Doubts About Agenus (NASDAQ:AGEN)
Mar 06Agenus: Making Another Effort With The FDA
Jan 25Agenus Inc.'s Imminent 1181/Bal Data Release And MiNK IPO Should Lead To Enormous Valuation Gains
Aug 25Agenus Multiple Value-Adding Events Ahead
Aug 18Party Time: Brokers Just Made Major Increases To Their Agenus Inc. (NASDAQ:AGEN) Earnings Forecasts
Aug 11Shareholder Returns
| AGEN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -3.8% | -2.7% |
| 1Y | -81.9% | -2.6% | 23.4% |
Return vs Industry: AGEN underperformed the US Biotechs industry which returned -2.6% over the past year.
Return vs Market: AGEN underperformed the US Market which returned 23.4% over the past year.
Price Volatility
| AGEN volatility | |
|---|---|
| AGEN Average Weekly Movement | 12.6% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: AGEN's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: AGEN's weekly volatility has decreased from 18% to 13% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 389 | Garo Armen | www.agenusbio.com |
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant.
Agenus Inc. Fundamentals Summary
| AGEN fundamental statistics | |
|---|---|
| Market cap | US$66.39m |
| Earnings (TTM) | -US$227.86m |
| Revenue (TTM) | US$160.43m |
0.4x
P/S Ratio-0.3x
P/E RatioIs AGEN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AGEN income statement (TTM) | |
|---|---|
| Revenue | US$160.43m |
| Cost of Revenue | US$189.10m |
| Gross Profit | -US$28.68m |
| Other Expenses | US$199.18m |
| Earnings | -US$227.86m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -9.71 |
| Gross Margin | -17.88% |
| Net Profit Margin | -142.03% |
| Debt/Equity Ratio | -4.9% |
How did AGEN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 22:01 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Agenus Inc. is covered by 14 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Colleen Kusy | Baird |
| Mayank Mamtani | B. Riley Securities, Inc. |
| Robert Wasserman | Dawson James Securities |